Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Biological: trastuzumab
Drug: irinotecan hydrochloride

First Posted Date: 2004-06-25

Last Posted Date: 2013-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT00003995

Locations: 🇺🇸
Sarah Cannon-Minnie Pearl Cancer Center, Nashville, Tennessee, United States
🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 2 locations

Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: triapine
Drug: irinotecan hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-06-11

Last Posted Date: 2013-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00084877

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2

Completed

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Diffuse Adenocarcinoma of the Stomach
Intestinal Adenocarcinoma of the Stomach
Mixed Adenocarcinoma of the Stomach
Recurrent Gastric Cancer
Stage IIIA Gastric Cancer
Stage IIIB Gastric Cancer
Stage IIIC Gastric Cancer
Stage IV Gastric Cancer

Interventions: Drug: irinotecan hydrochloride
Biological: bevacizumab
Drug: cisplatin
Procedure: computed tomography
Other: laboratory biomarker analysis

First Posted Date: 2004-06-11

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT00084604

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer
Diarrhea

First Posted Date: 2004-06-11

Last Posted Date: 2013-01-31

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00084721

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma

Phase 2

Completed

Conditions: Diffuse Adenocarcinoma of the Stomach
Stage IIIB Gastric Cancer
Adenocarcinoma of the Gastroesophageal Junction
Stage IIIC Gastric Cancer
Recurrent Gastric Cancer
Stage IV Gastric Cancer
Intestinal Adenocarcinoma of the Stomach
Mixed Adenocarcinoma of the Stomach
Stage IIIA Gastric Cancer

Interventions: Drug: oxaliplatin
Drug: irinotecan hydrochloride
Drug: capecitabine

First Posted Date: 2004-06-11

Last Posted Date: 2015-05-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00084617

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: docetaxel
Drug: gemcitabine hydrochloride
Drug: irinotecan hydrochloride

First Posted Date: 2004-05-25

Last Posted Date: 2016-07-20

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 80

Registration Number: NCT00004139

Locations: 🇺🇸
CCOP - Greenville, Greenville, South Carolina, United States
🇺🇸
Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States

and more 5 locations